Results 91 to 100 of about 3,395 (155)

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

Medicina
Background and Objectives: The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab are recently developed promising drugs used for treatment of familial hypercholesterolemia (FH).
Guoguang Xiao, Shan Gao, Yongmei Xie, Zhiling Wang, Min Shu   +4 more
doaj   +1 more source

A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels [PDF]

, 2016
PURPOSE OF THE STUDY: Statins and ezetimibe reduce low-density lipoprotein cholesterol (LDL-c) and cardiovascular disease (CVD) risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower LDL-c by 50%-70% and might be useful in ...
Abbas, Baigent, British Cardiac Society, Cannon, Cannon, Carl Groves, Caron, Chandrashekar Shetty, Cullen, Department of Health, Everett, Giunzioni, Izzat, Jarco, JBS3 Board, Julian Waldron, LaRosa, Mendis, Navarese, Nissen, Nissen, Ramachandran, Richard C Strange, Savarese, Sudarshan Ramachandran, Van Ganse, Waters   +26 more
core   +2 more sources

Alirocumab for the treatment of hypercholesterolaemia

Expert Review of Clinical Pharmacology, 2017
Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are unable to reach the recommended LDL-C targets.
DELLA PEPA, GIUSEPPE, BOZZETTO, LUTGARDA, ANNUZZI, GIOVANNI, RIVELLESE, ANGELA ALBAROSA   +3 more
openaire   +3 more sources

Efficacy and tolerability of evolocumab vs. ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial

, 2016
Importance: Muscle-related statin intolerance is reported by 5% to 20% of patients. Objective: To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and ...
, Ballantyne, Christie M, Brennan, Danielle M, Bruckert, Eric, Ceška, Richard, Dent-Acosta, Ricardo E, Elliott, Mary, Gouni-Berthold, Ioanna, Jensen, Henrik Kjærulf, Jeppesen, Jørgen, Lehman, Sam J, Lepor, Norman, Nissen, Steven E, Preiss, David, Rosenson, Robert S, Sattar, Naveed, Scott, Rob, Somaratne, Ransi, Stein, Evan A, Stroes, Erik, Wasserman, Scott M   +20 more
core   +2 more sources

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis

Scientific Reports
Recent case reports linked use of the lipid-lowering class of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to severe hypersensitivity reactions.
Foteini Dermiki-Gkana, Christopher A. Gravel, Christos Kontogiorgis, Antonios Douros   +3 more
doaj   +1 more source

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy

Endocrine Journal
Dyslipidemia has been considered a risk factor for diabetic peripheral neuropathy. Proprotein convertase subtilisin-like/Kexin 9 inhibitor (PCSK9) inhibitors are a new type of lipid-lowering drug currently in clinical use.
Na Cui, Yonghao Feng, Ming Wang, Xiuyan Lu, Yongmei Huang, Yinghui Chen, Xiaohong Shi   +6 more
doaj   +1 more source

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility

Качественная клиническая практика, 2018
Usage of PCSK9 inhibitors is a new approach of lipid lowering therapy allowing overcomes as well insusceptibility of standard statins’ therapy as their intolerance.
S. K. Zyryanov, I. N. Dyakov
doaj  

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In this post hoc analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, we evaluated the efficacy of alirocumab in patients with probable heterozygous ...
Gregory P. Geba, Kusha A. Mohammadi, Amy Damask, Charles Paulding, Luca A. Lotta, George Hindy, Robert Pordy, Garen Manvelian, Michael D. Shapiro, Vera A. Bittner, Deepak L. Bhatt, Michael Szarek, Gregory G. Schwartz, Ph. Gabriel Steg, Sergio Fazio   +14 more
doaj   +1 more source

PCSK9 antagonists and inflammation [PDF]

, 2018
Corsini, Alberto, Ferri, Nicola, Ruscica, Massimiliano, Sirtori, Cesare R.   +3 more
core   +1 more source

Análisis de las controversias en los niveles de colesterol-LDL como indicador de riesgo cardiovascular [PDF]

, 2018
[ES] Objetivo: analizar las controversias existentes entre las guías de práctica clínica actuales y esclarecer qué recomendaciones pueden estar mejor fundamentadas en evidencia sólida y cuales pueden tener evidencia más débil.
Zubiaur Zamacola, Jon
core